An autologous monocyte-derived dendritic cell vaccine pulsed with Epstein–Barr virus (EBV)-associated antigens. The ex vivo–generated dendritic cells present EBV antigens via MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing IFN-γ production and perforin/granzyme-mediated killing of EBV-positive lymphoma cells.
Autologous monocyte-derived dendritic cells pulsed with EBV antigens present peptides via MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing IFN-gamma production and perforin/granzyme-mediated killing of EBV-positive lymphoma cells.
YES
INDIRECT
DC vaccine primes EBV-specific CD8+ T cells that recognize EBNA3A-derived peptides on MHC I of EBV+ cells and kill them via perforin/granzyme-mediated cytotoxicity (with CD4+ help).
An autologous monocyte-derived dendritic cell vaccine pulsed with Epstein–Barr virus (EBV)-associated antigens. The ex vivo–generated dendritic cells present EBV antigens via MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing IFN-γ production and perforin/granzyme-mediated killing of EBV-positive lymphoma cells.
Autologous monocyte-derived dendritic cells pulsed with EBV antigens present peptides via MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing IFN-gamma production and perforin/granzyme-mediated killing of EBV-positive lymphoma cells.
YES
INDIRECT
Vaccine-primed EBV-specific CD8+ T cells recognize EBNA3B peptides on MHC I of EBV+ cells and kill them via perforin/granzyme-mediated cytolysis, supported by CD4+ T-cell help/IFN-γ.
An autologous monocyte-derived dendritic cell vaccine pulsed with Epstein–Barr virus (EBV)-associated antigens. The ex vivo–generated dendritic cells present EBV antigens via MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing IFN-γ production and perforin/granzyme-mediated killing of EBV-positive lymphoma cells.
Autologous monocyte-derived dendritic cells pulsed with EBV antigens present peptides via MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing IFN-gamma production and perforin/granzyme-mediated killing of EBV-positive lymphoma cells.
YES
INDIRECT
DC vaccine primes EBV-specific CD8+ T cells that recognize EBNA3C peptides on MHC I of EBV+ cells and kill them via perforin/granzyme-mediated cytotoxicity (with CD4+ help/IFN-γ support).
An autologous monocyte-derived dendritic cell vaccine pulsed with Epstein–Barr virus (EBV)-associated antigens. The ex vivo–generated dendritic cells present EBV antigens via MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing IFN-γ production and perforin/granzyme-mediated killing of EBV-positive lymphoma cells.
Autologous monocyte-derived dendritic cells pulsed with EBV antigens present peptides via MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing IFN-gamma production and perforin/granzyme-mediated killing of EBV-positive lymphoma cells.
YES
INDIRECT
The DC vaccine primes and expands EBV-specific CD8+ T cells that recognize EBNA‑LP–derived peptides on MHC I of EBV-positive cells and kill them via perforin/granzyme-mediated cytotoxicity (with CD4+ T-cell help and IFN-γ support).
An intravenous antibody–drug conjugate (ADC) targeting B7-H3 (CD276), linked to a cytotoxic topoisomerase I inhibitor payload. After binding B7-H3 on tumor cells, it is internalized and releases the payload to inhibit topoisomerase I, causing DNA damage and tumor cell death; dosed every 3 weeks in advanced solid tumors.
Monoclonal antibody targeting B7-H3 (CD276) that is internalized upon binding and releases a linked topoisomerase I inhibitor payload inside tumor cells, inhibiting topo I, inducing DNA damage, and causing tumor cell death.
YES
DIRECT
ADC binds B7-H3 on tumor cells, is internalized, and releases a topoisomerase I inhibitor payload that induces DNA damage, leading to apoptosis and cell death.